Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Revenue Drivers
ABBV logo

AbbVie Posts 9% Revenue Growth Amid Humira Decline and Pipeline Push

ABBV10-QFiling Date: 11/4/2025
AbbVie Inc.
Description

What this story covers

AbbVie's Q3 2025 10-Q shows 9% revenue growth to $15.8B, driven by Skyrizi (up 46%) and Rinvoq (up 34%), offsetting Humira's 56% drop. Strong cash flow ($13.8B), aggressive acquisitions, robust pipeline in immunology and oncology, and managed risks position the company for sustained diversification.

Story snapshot

CompanyAbbVie Inc.
TickerABBV
VariantStandard detailed
Duration11:00
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001551152-25-000049

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in